Page last updated: 2024-12-06

hymenovin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hymenovin is a naturally occurring compound with a complex structure containing a unique spiroketal ring system. It has been isolated from the fungus *Hymenoscyphus ericae*. Hymenovin exhibits a wide range of biological activities, including anti-inflammatory, antifungal, and cytotoxic effects. It has been shown to inhibit the growth of various cancer cell lines, and its potential as a therapeutic agent is currently being investigated. Research interest in hymenovin stems from its promising biological activities and its unique chemical structure, which presents a challenge for synthetic chemists. The synthesis of hymenovin remains a significant hurdle, with various approaches explored, including biocatalytic methods.'

hymenovin: major toxic constituent of poisonous range plant Hymenoxys odorate; shown to be mutagenic; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Hymenoxysgenus[no description available]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]

Cross-References

ID SourceID
PubMed CID42295
CHEBI ID5826
MeSH IDM0064436

Synonyms (25)

Synonym
57074-51-8
nsc-217313
5,7-dihydroxy-4a,9-dimethyl-3-methylenedecahydrofuro(2',3':5,6)cyclohepta(1,2-c)pyran-2(3h)-one
hymenoxone
hsdb 3495
furo(2',3':5,6)cyclohepta(1,2-c)pyran-2(3h)-one, decahydro-5,7-dihydroxy-4a,9-dimethyl-3-methylene-, (3ar,4as,5r,7r,8ar,9r,10ar)-
furo(2',3':5,6)cyclohepta(1,2-c)pyran-2(3h)-one, decahydro-5,7-dihydroxy-4a,9-dimethyl-3-methylene-
furo(2',3':5,6)cyclohepta(1,2-c)pyran-2(3h)-one, decahydro-5,7-dihydroxy-4a,9-dimethyl-3-methylene-, (3ar-(3a-alpha,4a-beta,5-alpha,7-beta,8a-alpha,9-alpha,10a-alpha))-
hymenovin
hsdb 3494
C09482
57377-32-9
hymenoxon
ayr8b2nt77 ,
unii-ayr8b2nt77
nsc 217313
hymenoxone [hsdb]
furo(2',3':5,6)cyclohepta(1,2-c)pyran-2(3h)-one, decahydro-5,7-dihydroxy-4a,9-dimethyl-3-methylene-, (3ar,4as,5r,7r,8as,9r,10ar)-
furo(2',3':5,6)cyclohepta(1,2-c)pyran-2(3h)-one, decahydro-5,7-dihydroxy-4a,9-dimethyl-3-methylene-, (3ar-(3a.alpha.,4a.beta.,5.alpha.,7.beta.,8a.alpha.,9.alpha.,10a.alpha.))
CHEBI:5826
(1r,3r,4as,5r,6ar,9ar,10as)-1,3-dihydroxy-5,10a-dimethyl-9-methylene-3,4,4a,5,6,6a,9a,10-octahydro-1h-furo[3,4]cyclohepta[5,7-d]pyran-8-one
Q27106901
(1s,3r,7r,9r,10s,12r,14r)-12,14-dihydroxy-1,9-dimethyl-4-methylidene-6,13-dioxatricyclo[8.4.0.03,7]tetradecan-5-one
DTXSID601104051
(3ar,4as,5r,7r,8as,9r,10ar)-decahydro-5,7-dihydroxy-4a,9-dimethyl-3-methylenefuro[2',3':5,6]cyclohepta[1,2-c]pyran-2(3h)-one

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Hymenoxon and helenalin are toxic sesquiterpene lactones present in the toxic range plants Hymenoxys odorata and Helenium microcephalum."( Role of glutathione in the toxicity of the sesquiterpene lactones hymenoxon and helenalin.
Hayes, MA; Kim, HL; Merrill, JC; Murray, CA; Safe, S, 1988
)
0.27
" Bitteerweed contains a toxic sesquiterpene lactone, hymenoxon, the toxicity of which is reduced by cysteine."( Protective effects of antioxidants on bitterweed (Hymenoxys odorata DC) toxicity in sheep.
Anderson, AC; Calhoun, MC; Herrig, BW; Jones, LP; Kim, HL, 1982
)
0.26
" The LD50 of hymenoxon following carbon tetrachloride pretreatment was increased to 630 +/- 20."( Toxicity of hymenoxon in Swiss white mice following pretreatment with microsomal enzyme inducers, inhibitors and carbon tetrachloride.
Jones, DH; Kim, HL, 1981
)
0.26
"The oral LD50 of hymenoxon in Swiss white mice was found to be 241 +/- 37 mg/kg."( Toxicity and mutagenicity of hymenoxon, sequiterpene lactone.
Jones, DH; Kim, HL, 1981
)
0.26

Dosage Studied

ExcerptRelevanceReference
" Hymenoxon, isolated from Hymenoxys odorata DC, was dissolved in dimethyl sulfoxide (DMSO) and water (1:1, v/v) and was administered daily at a dosage level of 100 mg/kg of body weight for 5, 10, or 20 days."( Acute exposure to hymenoxon: electron microscopic study of the mouse liver.
Bowers, DE; Dunlap, MK; Jones, DH; Sampson, HW, 1984
)
0.27
" There was no dosage of L-cysteine that significantly changed the survival time for fatally intoxicated sheep."( The antagonistic effect of L-cysteine in experimental hymenoxon intoxication in sheep.
Camp, BJ; Kim, HL; Rowe, LD, 1980
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oxanesAny organic heteromonocyclic compoundthat is oxane or its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (95.00)18.7374
1990's1 (5.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.13 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]